Business Development

Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The pharma company was...

Challenge: A pharmaceutical company was actively searching for strategic partnering opportunities to expand its pipeline and had commissioned Alacrita to conduct a comprehensive pre-due diligence...

Challenge: A pharmaceutical company with an established gene-therapy franchise wanted to expand its oncology pipeline through external licensing. Among several options, the deal team had identified...

Challenge: A mid-cap pharmaceutical company exploring licensing and co-development opportunities in women’s health identified a promising early-stage startup. With limited internal resources...

Challenge: A generalist investment fund with limited experience in the pharmaceutical sector was evaluating a co-investment opportunity in an early-stage therapeutic project targeting novel...

Challenge: Our client, a private equity-backed specialty pharmaceutical company experiencing rapid growth through mergers and acquisitions, was actively evaluating several late-stage development...

Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs) but not due to...

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: Our client was advising principal investors on a possible transaction to cover the development and commercialization of a product targeting chemotherapy-induced anemia (CIA). Alacrita was...

Challenge: A UK investment company was considering leading an investment round in a UK-based platform technology company utilizing induced pluripotent stem cells (iPSCs) in disease models as R&D...